Kodiak Sciences Files for IPO to Fund Global AMD Eye-Drug Studies | Enterpreneurship

Want create site? Find Free WordPress Themes and plugins.

Many patients with the more severe form of age-related macular degeneration, a type of vision loss, have trouble with the standard treatment—a once-monthly injection into the eye.

Kodiak believes it can do better with an experimental drug that may require less frequent injections and the company has filed for an IPO to finance a slate of global clinical studies. Palo Alto, CA-based Kodiak set a preliminary $100 million target for its stock offering. The company has applied for a listing on the Nasdaq exchange under the stock symbol “KOD.” (Kodiak is not to be confused with Cambridge, MA-based Codiak BioSciences.)… Read more »


Did you find apk for android? You can find new Free Android Games and apps.

You might also like More from author

Leave A Reply

Your email address will not be published.